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Lower respiratory infections (LRIs) are estimated to account for 38.6% of infectious disease deaths and 14.9% of all deaths in African children1. These deaths are largely preventable; in 
particular, reducing risk factors such as household air pollution, 
stunting and no or partial breastfeeding have been shown to pro-
tect children against infection and death resulting from infection2. 
In addition, there are several direct interventions that can prevent 
or treat infections3, including vaccines to the predominant causes 
of LRI4,5, most notably Streptococcus pneumoniae, which is esti-
mated to be responsible for 46.7% of LRIs across Africa6. Moreover, 
proven treatments such as antibiotics and supplemental oxygen can 
prevent death once an individual is infected3,7. Although childhood 
deaths due to LRIs are estimated to have fallen by more than 28.5% 
in Africa since 2000, this reduction is not geographically uni-
form, and LRIs still caused more than 432,000 deaths in children 
under 5 in 2017 (ref. 1). In response, the Global Action Plan for the 
Prevention and Control of Pneumonia and Diarrhoea (GAPPD) 
of the World Health Organization has called for the trichotomy of 
‘protect, prevent and treat’8. The immediate need to assemble and 
analyse all available subnational data on the causes and drivers of 
LRIs was identified as key to empowering policy aimed at reducing 
LRI burden.
In 2013, the GAPPD established the goal of reducing child mor-
tality rates attributable to LRIs to below 3 in 1,000 persons and 
reducing severe LRI episodes to 75% of the 2010 values by 2025 
(ref. 8). Identifying areas or geographical clusters with the high-
est residual LRI burden is key to reducing the number of episodes 
and deaths due to LRI. Of more practical importance, identify-
ing vulnerable populations that are either more likely to become 
infected by vaccine-preventable aetiologies or more likely to die 
once infected due to inadequate treatment can optimize targeted 
intervention strategies. Given the substantial subnational variation 
in other risk factors and causes of under-5 mortality9,10, as well as 
under-5 mortality itself11, country-level estimates of LRI burden 
probably mask these vulnerable populations. To fully understand 
the relative local drivers and causes of under-5 mortality, accurately 
capturing the covariation in risk factors and associated diseases is of 
paramount importance.
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Lower respiratory infections (LRIs) are the leading cause of death in children under the age of 5, despite the existence of vac-
cines against many of their aetiologies. Furthermore, more than half of these deaths occur in Africa. Geospatial models can 
provide highly detailed estimates of trends subnationally, at the level where implementation of health policies has the greatest 
impact. We used Bayesian geostatistical modelling to estimate LRI incidence, prevalence and mortality in children under 5 sub-
nationally in Africa for 2000–2017, using surveys covering 1.46 million children and 9,215,000 cases of LRI. Our model reveals 
large within-country variation in both health burden and its change over time. While reductions in childhood morbidity and 
mortality due to LRI were estimated for almost every country, we expose a cluster of residual high risk across seven countries, 
which averages 5.5 LRI deaths per 1,000 children per year. The preventable nature of the vast majority of LRI deaths mandates 
focused health system efforts in specific locations with the highest burden.
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Precision public health focuses on identifying populations in 
need of specific interventions and providing those interventions 
in a timely manner12,13; as such, spatially and temporally resolved 
estimates of disease burden are needed to inform targeted inter-
ventions. The health burden of LRIs in children is dominated by 
mortality and not morbidity; thus, reducing LRI burden must ulti-
mately reduce LRI deaths. This starts with geospatial mapping of 
incidence and mortality of LRIs in children and the risk factors 
most associated with these diseases. In addition, the case fatal-
ity rate (CFR), defined as the ratio of mortality to incidence, is an 
indicator of treatment-seeking practices and disease management. 
While some CFR interventions focus on the ‘protect’ component of 
the GAPPD guidelines, by improving a child’s overall health from 
birth, a number of more proximal interventions can greatly improve 
the prognosis of a child’s LRI disease in a clinic or hospital setting3. 
Although national estimates exist1,2, policy decisions and interven-
tions rarely occur uniformly at the country level. Similarly, local 
variation in LRI incidence or mortality may be obscured by esti-
mates restricted to national levels, hindering the ability to identify 
clusters or hotspots of LRI burden that cross administrative bound-
aries. While some risk factors for LRIs such as stunting14 and no or 
partial breastfeeding15 have been estimated subnationally, with con-
siderable subnational heterogeneity, there are only a few analyses of 
spatial and spatiotemporal variation in LRI burden within selected 
regions in Africa16–18, and there has not been a comprehensive, sub-
national analysis of LRI burden for the continent as a whole.
In this study, we present a systematic, comprehensive analysis of 
local variation in LRI morbidity and mortality in children under 
5 across Africa between 2000 and 2017. We use Bayesian model-
based geostatistics and an extensive geolocated dataset—describ-
ing 9,215,000 LRIs across 1.46 million children from 45,719 total 
data points, corresponding to 43,080 geolocated point-level survey 
clusters and 2,639 subnational, geolocated polygons—in combina-
tion with established methods from the Global Burden of Disease 
(GBD) 2017 study1,19 to estimate posterior distributions of con-
tinuous continent-wide surfaces of LRI prevalence, incidence and 
mortality. We then use repeated draws from these posterior distri-
butions and aggregate and summarize these to relevant administra-
tive subdivisions (for example, the first administrative level, such as 
‘districts’ in Uganda or ‘divisions’ in Kenya; hereafter referred to as 
‘divisions’) to identify those with a higher-than-average burden. We 
juxtapose subnational results with national-level estimates derived 
from the GBD 2017 to provide further context. Finally, we overlay 
these results onto detailed analyses of both the percentage of all LRI 
deaths attributable to S. pneumoniae and to LRI CFRs to identify 
regions of Africa most in need of improved vaccine coverage or case 
management, respectively.
We conduct out-of-sample tests of model fit and model speci-
fication using fivefold cross-validation strategies. At the first 
administrative level, our estimates closely match the survey data 
(Supplementary Figs. 15 and 16). A full description of the data, 
modelling approaches and validation techniques can be found in the 
Methods. The full output of the analyses is publicly available in the 
Global Health Data Exchange (http://ghdx.healthdata.org/record/
ihme-data/africa-under-5-lri-incidence-prevalence-mortality-geo-
spatial-estimates-2000-2017) and can be explored further via a cus-
tom data visualization tool (https://vizhub.healthdata.org/lbd/lri).
Results
Substantial subnational heterogeneity in LRI mortality and mor-
bidity through time. In 2017, there were an estimated 23.6 million 
(95% uncertainty interval (UI) 21.2–27.4) incident LRI episodes in 
children across all of Africa. Given the 56% increase in the population 
of children under the age of 5 in Africa, this is a moderate increase in 
LRI episodes from 20.6 million (UI 19.9–21.3) in 2000 (Fig. 1a,b). The 
average incidence rate of LRI for African children in 2000 was 165.8 
episodes (UI 160.1–171.9) per 1,000, and this rate decreased to 122.2 
episodes (UI 109.7–141.6) per 1,000 in 2017 (Fig. 1c,d). According to 
country estimates derived from the GBD 2017 study, the largest abso-
lute decrease at a national level took place in Angola, where the rate 
of incident episodes was 165.0 episodes (UI 147.0–183.7) per 1,000 
in 2000, decreasing to 83.0 episodes (UI 70.8–96.7) per 1,000 in 2017 
(ref. 6). The greatest absolute decline in LRI rates among all divisions 
in Africa occurred in the Blue Nile state, Sudan, from 419.9 episodes 
(UI 383.0–458.0) per 1,000 in 2000 to 222.1 episodes (UI 62.1–508.5) 
per 1,000 in 2017 (Fig. 1c,d). In 2017, four countries had greater than 
threefold variation between divisions: Nigeria; Somalia; Ethiopia; and 
Senegal. For example, in Nigeria, Yobe had some of the highest rates 
of LRI episodes across all of Africa in 2017 (148.6 episodes (UI 133.6–
164.6) per 1,000), while Anambra had rates less than a quarter of that 
rate (32.3 episodes (UI 25.2–40.8) per 1,000) (Fig. 1d).
In spite of general declines in incidence across Africa, the 
GAPPD goal of decreasing severe incidence by 75% of its 2010 
values by 2025 is ambitious. It is difficult to evaluate this goal sub-
nationally, since severity data are scarce at the first administrative 
level. However, under the simplifying assumption that severe inci-
dence is a constant proportion of all incidence across geographies, 
years, sexes and ages, extremely few divisions are on pace to hit the 
goal by the 2025 deadline (Supplementary Fig. 2).
There were 432,000 (UI 404,000–461,000) LRI deaths estimated 
among African children in 2017, an average mortality rate of 2.3 (UI 
2.1–2.4) deaths per 1,000 (Fig. 2b,d)1. This was a substantial decline 
from numbers in 2000 where the total estimated number of African 
children who died from LRIs was 604,000 (UI 576,000–636,000) and 
the average LRI death rate was 4.9 per 1,000 (UI 4.6–5.1) (Fig. 2a,c). 
Among regions with a mortality rate of at least 2 per 1,000 in 2017, 
we found increases in 14 divisions from five countries: Burkina Faso 
(Centre, containing 328,000 children); Chad (Mandoul and Moyen-
Chari regions, containing collectively 311,000 children); Central 
African Republic (Lobaye and Ouham-Pendé prefectures, contain-
ing collectively 195,000 children); South Sudan (Central, Eastern and 
Western Equatoria, containing collectively 660,000 children); and 
Zimbabwe (Manicaland, Mashonaland West, Masvingo, both North 
and South Matabeleland and Midlands provinces, containing col-
lectively 1.86 million children) (Fig. 2c,d). Despite a general pattern 
of decreasing rates, we found that mortality rates were consistently 
high throughout the study period in the Central African Republic 
(CAR), Chad, Nigeria and South Sudan (Figs. 2c,d and 3). In 2017, 
the largest mortality rate difference within a single country’s divi-
sions was observed in Nigeria, with estimates ranging from 1.8 (UI 
1.4–2.2) deaths per 1,000 in Anambra to 9.2 (UI 8.1–10.4) deaths per 
1,000 in Yobe (Fig. 2d). The largest number of LRI deaths in any divi-
sions in 2017 occurred in Nigeria and Ethiopia; in particular, Kano 
and Kaduna states in Nigeria (13,800 (UI 12,200–15,500) deaths and 
11,500 (UI 9,800–13,300) deaths, respectively) and Oromia state in 
Ethiopia (12,000 (UI 10,400–13,800) deaths) (Figs. 2b and 3).
In contrast to the severe incidence GAPPD goal, many divisions 
in Africa appear to have met the GAPPD mortality goal of <3 deaths 
per 1,000 children (Supplementary Fig. 3). There were 40 countries 
where every division appeared to have reduced LRI mortality below 
3 in 1,000 and 49 countries with at least 1 division at or below the 
target (Supplementary Table 10). This is in contrast to the situation 
in 2010, when only 27 countries had completely met the goal and 46 
countries had at least 1 division below the threshold (Supplementary 
Table 10). At the current rate of decline (Supplementary Fig. 3a,b), 
we expect only 11 countries to have divisions failing to hit the 
GAPPD mortality goal by 2025 (Supplementary Table 10).
Concentration of LRI mortality burden. Substantial geographi-
cal heterogeneity in LRI mortality risk over time was also apparent 
from our clustering analyses. Using the Getis–Ord local G statistic, 
36 divisions across nine countries (Benin, CAR, Niger, Sierra Leone, 
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Chad, Cameroon, Nigeria, Somalia and Angola) were hotspots of 
mortality risk in 2000 (Fig. 2e). By 2017, a large, contiguous residual 
hotspot spanning 54 divisions across seven countries in CAR, South 
Sudan, Chad, Niger, Cameroon, Democratic Republic of the Congo 
(DRC) and Nigeria was observed (Fig. 2f). This single, transnational 
cluster accounted for 30.7% (UI 29.1–32.6) of all child deaths from 
LRI while including only 13.0% of the population of African children 
under 5 in 2017. Two sensitivity analyses found that these results 
were consistent across the posterior distribution of fitted values as 
well as in settings where all spatial and temporal autocorrelations had 
been removed from the model fitting process (Supplementary Fig. 6).
Unsurprisingly, countries that were large and consistent contribu-
tors to both the 2000 hotspots and residual hotspot in 2017 were those 
with the most modest relative reductions in mortality rate over the 
Millennium Development Goal period (1990–2017 reduction: CAR, 
17.4% (UI −23.5–46.9); DRC, 52.2% (UI 34.6–64.3); Chad, 42.0%, 
(UI 20.7–57.8); Nigeria, 59.6%, (UI 46.0–69.7); and South Sudan, 
31.9% (UI −1.6–54.3), as derived from the GBD 2017 data). While 
these reductions are substantial, they are behind the average reduc-
tion across Africa over this period (66.0% decrease (UI 51.2–76.7)).
Potential for targeted interventions to reduce the LRI burden. 
Understanding which subnational regions have the highest remaining 
LRI burden is a first step towards reducing burden. Nearly half of 
all childhood LRI deaths in Africa are attributable to S. pneumoniae 
(201,000 (UI 99,100–317,000) deaths)1, but as with all-cause LRI 
mortality, the burden of LRIs attributable to S. pneumoniae has sub-
stantially fallen across almost all of Africa since 2000, with the nota-
ble exception of Zimbabwe, where S. pneumoniae mortality rates 
have increased by 40.3% (Fig. 4a). Although the current pneumo-
coccal conjugate vaccines (PCVs) are not perfectly effective and do 
not cover all S. pneumoniae serotypes currently causing mortality 
and morbidity in Africa20, they are still a potent tool to prevent LRIs. 
While PCV was only introduced in select African countries over 
the last decade21, it is already clear that PCV is contributing to the 
reduction of burden in the countries where it has been introduced6. 
It is likewise clear that there is still a considerable unmet need for 
higher PCV coverage. South Sudan has the highest S. pneumoniae 
mortality rate at 3.4 (UI 1.7–5.5) deaths per 1,000 (Fig. 4a) and cur-
rently has no PCV programme. Following aetiological fraction cal-
culations from the GBD study2 (see Methods for more details), we 
estimated a 23.5% (UI 14.7–32.4) reduction in this mortality rate is 
possible with complete childhood PCV coverage, which would avert 
0.8 (UI 0.2–1.8) deaths per 1,000 children, or 1,800 (UI 550–4,100) 
childhood deaths annually—350 (UI 110–790) from the division 
of Central Equatoria alone (Fig. 4b–d). Conversely, Nigeria has an 
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Fig. 1 | LRI incidence among children under 5 in 2000 and 2017. a,b, Estimated mean number of LRI episodes aggregated to the first-level administrative 
subdivision for 2000 (a) and 2017 (b). c,d, Estimated LRI episodes rate per 1,000 children aggregated to the first-level administrative subdivision for  
2000 (c) and 2017 (d). Areas with fewer than 10 people per 1 × 1 km2 or classified as ‘barren or sparsely vegetated’ are coloured in grey.
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Fig. 2 | LRI mortality rate, number of deaths and clustering of risk among children under 5 in 2000 and 2017. a,b, Estimated mean number of  
LRI deaths aggregated to the first-level administrative subdivision for 2000 (a) and 2017 (b). c,d, Estimated mean mortality rate per 1,000 children  
due to LRI aggregated to the first-level administrative subdivision for 2000 (c) and 2017 (d). e,f, z-scores as determined by the hotspot analysis for  
2000 (e) and 2017 (f). Discontinuities in the colour scale at −3.8 and 3.8 correspond to locations identified as coldspots or hotspots, respectively  
(based on adjustments for multiple hypotheses tests). Areas with fewer than 10 people per 1 × 1 km2 or classified as ‘barren or sparsely vegetated’ are 
coloured in grey.
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extremely high LRI burden and a much larger population, but it 
has a PCV programme, with a country-wide estimated 35.3% (UI 
22.1–48.3) coverage of PCV13 (ref. 22). This programme is already 
estimated to be saving 4,400 (UI 2,700–5,900) children per year, but 
complete coverage (an unlikely scenario) could avert an additional 
14,400 (UI 8,600–20,000) deaths per year, reducing the S. pneu-
moniae mortality rate in Nigeria by a further 18.8% (UI 11.4–25.2) 
(Fig. 4b–d). To date, reliable subnational estimates of PCV coverage 
are not yet available, but under a conservative assumption that PCV 
coverage rates in the regions of Nigeria with the highest all-cause 
LRI burden are at best no higher than the country-wide average, 
over 3,200 (UI 1,900–4,300) additional childhood deaths per year 
could be averted in the Yobe and Kaduna states alone with com-
plete childhood PCV coverage (Fig. 4d). Since it is plausible that the 
regions with the highest LRI burden are also the regions with the 
lowest PCV coverage, these estimates may drastically underestimate 
potential vaccine impact.
As with overall LRI burden, a crucial step in targeting interven-
tions is identifying where LRI CFRs remain highest. Across Africa in 
2017, the CFR for childhood LRI was 18.3 (UI 16.3–19.8) per 1,000 
and was estimated to be ≥30 per 1,000 in eight countries: Benin; 
Burkina Faso; CAR; Chad; Mali; Niger; Nigeria and South Sudan, 
compared to 18 countries in 2000 (Fig. 5a, secondary analysis of the 
results from the GBD 2017 study). CFRs may obscure the differ-
ence between locations where the rates in both the numerator and 
denominator are high and those where both rates are low; regions 
of mortality and incidence rate space that result in similar CFRs are 
indicated by differently shaded regions in Fig. 5b–f. Many countries 
in the Middle East had low mortality rates in spite of relatively high 
incidence rates, while in central sub-Saharan Africa many countries 
had low incidence but relatively high mortality. Both CAR and Mali 
had a CFR of approximately 38 per 1,000 episodes in 2017 (37.9 
(UI 23.8–55.9) per 1,000 for CAR, 37.5 (UI 24.1–53.4) per 1,000 for 
Mali), but the mortality rate in CAR (5.1 (3.4–7.0) deaths per 1,000) 
was over twice the mortality rate in Mali (2.4 (1.7–3.2) deaths per 
1,000) (Figs. 5a and 2d). Simultaneously, due to substantial differ-
ence in the populations of the two countries, the total number of 
childhood deaths attributable to LRI in Mali (8,890 (7,540–9,300) 
deaths) was over twice that of CAR (3,090 (2,030–4,270) deaths) 
(Fig. 2b). In the year 2000, 17 countries were estimated to have inci-
dence and mortality rates that were above the median rates of 154 
incident episodes per 1,000 and 3.7 deaths per 1,000 for the conti-
nent. By 2017, only South Sudan remained above the 2000 median 
rates for both mortality and incidence (Fig. 5b–f). In 2017, mor-
tality rates remained above the 2000 median in CAR (5.1 (3.4–7.0) 
deaths per 1,000), Chad (4.7 (3.6–5.9) deaths per 1,000), Nigeria 
(4.4 (3.3–5.7) deaths per 1,000) and South Sudan (5.3 (3.9–7.1) 
deaths per 1,000).
Discussion
Over the Millennium Development Goal period (1990–2015), dra-
matic declines at the national scale were documented across Africa, 
with most countries (42 of 52) reducing their under-5 LRI mortality 
rate by at least 40%1. We found that the rates of decline in incidence 
and mortality varied both between and within countries across first-
level administrative divisions. Some countries had substantial and 
uniform reductions in LRI burden, while others performed less well 
in some areas. The divisions that struggled most were clustered into 
a single region spanning seven countries. Many of these divisions 
have had consistently high risks over the past 18 years, indicating 
that they have long been vulnerable. However, identifying the pres-
ence (and emergence) of this clustered region represents a unique 
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(14) Katsina (6.23) 49%
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(22) Logone Occidental (5.59) 56%
(26) Juba Hoose (5.4) 67%
(29) Zamfara (5.25) 64%
(34) Juba Dhexe (5.13) 71%
(86) Migori (3.44) 71%
Number of deaths
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(1) Oromia (31,619.62)
(2) Kano (22,144.58)
(3) SNNPR (18,506.37)
(4) Katsina (16,831.07)
(5) Orientale (16,685.31)
(6) Amhara (16,114.86)
(7) Kaduna (14,596.5)
(8) Jigawa (13,402.56)
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(15) Borno (9,746.49)
2017
(1) Kano (11,490.41) 48%
(2) Kaduna (9,537.75) 35%
(3) Oromia (8,825) 72%
(4) Katsina (8,604.08) 49%
(5) Bauchi (7,282.4) 39%
(6) Jigawa (7,064.91) 47%
(7) Orientale (6,895.06) 59%
(8) Amhara (5,795.01) 64%
(9) SNNPR (5,675.07) 69%
(10) Borno (4,997.16) 49%
(11) Sokoto (4,784.96) 61%
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a b
Fig. 3 | LRI mortality rate and number of deaths among children under 5 by first-level administrative subdivision, 2000 and 2017. a, The 10 first-level 
administrative subdivisions with the highest mortality rates (per 1,000) associated with LRIs in 2000 and 2017. b, The 10 first-level administrative 
subdivisions with the highest number of childhood deaths associated with LRIs in 2000 and 2017. Regions not in the top 10 in both 2000 and 2017 are 
listed below the vertical ellipses with their associated year-specific rank. The lines connecting regions are solid if the rank increased from 2000 to 2017 
and dashed if the rank decreased. Relative change in values is shown for 2017. SNNPR, Southern Nations, Nationalities, and Peoples’ Region.
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opportunity for targeting interventions to those in most need. As 
demonstrated in southern Africa2,23, great successes are possible 
even in high-risk areas.
A recent country-level study found that expanded Haemophilus 
influenzae type b vaccine and PCV coverage and lower exposure 
to indoor air pollution were the leading independent drivers of 
declining under-5 LRI mortality in southern sub-Saharan Africa2. 
In Botswana, for example, under-5 LRI deaths declined by an esti-
mated 20.5% due to expanded access to PCV and by 11.0% due to H. 
influenzae type b vaccine coverage2. A more in-depth spatiotempo-
ral analysis of the factors that lead to this and other successes could 
help identify important strategies for reducing both LRI incidence 
and CFR in the mapped high-risk areas.
The GAPPD framework to ‘protect, prevent and treat’ can 
guide intervention strategies depending on the local transmis-
sion setting. For example, Ethiopia has a below-average CFR, but 
partially due to its population size, it contains 3 of the top 10 divi-
sions where the most children under 5 die from LRIs (Figs. 5a and 
3b). Interventions in Ethiopia should increasingly emphasize pre-
vention, since their treatment rates are already among the best in 
Africa; however, due to their high population, they still have a con-
siderable LRI burden22. By contrast, Nigeria currently has the high-
est CFR in Africa; thus, interventions that emphasize effective and 
timely treatment will have a large impact. Nigeria, like a few other 
countries in central sub-Saharan Africa, has both high CFRs and 
high incidence rates. As such, interventions focused on preventing 
infections (such as improved vaccine coverage) would likewise have 
substantial impact. The local distribution of risk factors—including 
indoor and outdoor air pollution, child growth failure, poor PCV 
and H. influenzae type b vaccine coverage and inadequate antibi-
otic use—could be combined with our morbidity and mortality 
estimates to create locally tailored intervention suites. Critically, in 
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Fig. 4 | LRI mortality rate attributable to S. pneumoniae among children under 5 in 2000 and 2017. a, S. pneumoniae LRI mortality rate per 1,000 episodes 
for each country (indicated by the ISO3 abbreviations; www.iso.org/obp/ui) in 2000 and in 2017. b, The same mortality rate in 2017 in black, with the blue 
regions indicating gains made due to current PCV coverage and the orange regions indicating remaining reductions possible with perfect PCV coverage. 
Countries are plotted in order of the current mortality rate. c, The plot from b reoriented to illustrate the absolute difference in current mortality rate versus 
a baseline of no PCV deployment. The height of the orange bar indicates the remaining gain available in mortality rate given 100% PCV coverage. d, Same 
information as c but by total number of avertable deaths. Countries in purple are in western sub-Saharan Africa, countries in light green are in central  
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are in North Africa. The arrows indicate countries located in the 2017 residual hotspot.
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circumstances where increased antibiotic use is recommended, care 
must be taken to balance optimal intervention for the specific local 
conditions while simultaneously minimizing risk for an increase in 
antibiotic resistance24.
These results are subject to several limitations. First, to produce 
continent-wide estimates, we make assumptions about data qual-
ity and consistency across a range of sources. For example, LRI 
prevalence surveys rely on self-reported data on cough and difficulty 
breathing and are subject to reporting and recall bias; we assume 
the same level of recall bias across all surveys25. Additionally, con-
versions from prevalence to incidence, estimates of the burden 
of S. pneumoniae, PCV coverage and the CFR analysis all lever-
age the GBD 2017 study modelled estimates, but GBD assumes 
that relationships and coverage values are constant within each 
country. While the conversion from incidence to mortality derived 
from the GBD study combines various data sources and allows for 
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variation in CFR by country, year, sex and age, it does not currently 
incorporate the effects of comorbidities. Our geospatial approach 
borrows strength from neighbouring areas and may smooth over 
spatially or temporally focal epidemics. Furthermore, while the use 
of a continuous risk surface is a common approach for determining 
local risk, accounting for population movement and the clustered 
nature of populations in rural areas may improve local estimates. 
Our approach is focused on optimal prediction, not inference, and 
thus the fitted surfaces are not the optimal tool for assessing the 
impact of risk factors on risk. Regarding the post-hoc clustering 
analysis, these approaches, conducted on the modelled surfaces 
as opposed to the actual data, are used as indices of clustering as 
opposed to formal statistical tests. In addition, focused clustering 
analyses could also include more direct clustering approaches26,27, 
but given the coherent nature of the single clustered region iden-
tified, it is unlikely that those analyses would yield fundamentally 
different qualitative conclusions. Finally, there is strong evidence of 
age-related difference in risk within the 0–5 year age group, espe-
cially by aetiology28,29. Due to the nature of the data and methods 
we use, we are currently unable to parse mortality and morbidity 
estimates into finer age groups or split this burden by aetiology.
The burden of LRI in Africa has fallen dramatically since 2000, but 
this remarkable progress has not been universal across the continent. 
The estimates provided in this analysis illustrate the substantial local 
variability in childhood morbidity and mortality due to LRI, both 
across Africa and within individual countries. In particular, a single 
clustered region disproportionately contains much more risk than 
the rest of Africa. Exemplifying the local variability in risk, no entire 
country is contained within this region. Rather, subnational portions 
of countries may be identified as being part of the clustered resid-
ual hotspot. As Africa moves towards the 2025 GAPPD goals, those 
countries that are lagging behind will need specific, detailed focus to 
make satisfactory progress. The work presented in this study can be 
combined with targeted interventions to help children in the regions 
that are most neglected to reduce the mostly avertable burden of LRI.
Methods
Overview. For this study, LRIs were defined as diseases of the lower airways 
including pneumonia and bronchiolitis. Severe LRI episodes, which we present 
in this study, are those requiring inpatient medical treatment as determined by a 
physician and based on World Health Organization Integrated Management of 
Childhood Illness guidelines30. Prevalence, incidence and mortality were modelled 
on continuous continent-wide surfaces and were subsequently aggregated to the 
first-level administrative subdivisions (referred to as divisions). This study complies 
with the Guidelines for Accurate and Transparent Health Estimates Reporting 
recommendations (Supplementary Table 1)31. Additional results are provided in the 
Supplementary Information and online (https://vizhub.healthdata.org/lbd/lri).
Data sources, standardization and transformations. We compiled 191 
household surveys (including the Demographic and Health Surveys, Multiple 
Indicator Cluster Surveys, World Bank and other country-specific surveys) from 
2000 to 2017 with geocoded information from 45,719 total data points, 43,080 
corresponding to survey clusters and 2,639 to subnational polygon boundaries. We 
included surveys that asked about 2- or 4-week prevalence of cough with difficulty 
breathing among children either under 3 or under 5 years old and allowed for 
geolocation below the country level. The prevalence of acute respiratory infection 
symptoms was adjusted to meet a standard case definition for LRIs (clinician-
diagnosed pneumonia or bronchiolitis). The transformation of seasonally adjusted 
prevalence data from period to point estimates is described in detail in the GBD 
2016 study of global, regional and national LRI mortality and morbidity2.
We differentially scaled our continuous continent-wide surface estimates of 
the spatial pattern of prevalence to national-level estimates of LRI prevalence and 
incidence from the GBD 2017 study by calculating a population-weighted mean 
such that the national estimates presented in this study match those from the 
GBD 2017 study. To produce the severe incidence estimates, we multiplied our 
prevalence estimates by the GBD fraction of LRI episodes categorized as severe 
divided by average duration. CFRs by country and year were obtained from the 
GBD by dividing the country-specific mortality of LRI in a given year by the 
country-specific total incidence in that year. Finally, we estimated our continuous 
continent-wide surface of mortality by multiplying our incidence surface by the 
appropriate country-year CFRs. Detailed data processing descriptions are provided 
in Section 2.0 of the Supplementary Information.
Estimation of spatially explicit LRI prevalence and clustering. Adjusted 
point prevalence data were used as inputs to a Bayesian model-based 
geostatistical framework (described in detail in Section 3.3 in the Supplementary 
Information)2,19. Briefly, this framework uses a spatially and temporally explicit 
hierarchical logistic regression model to predict LRI prevalence in locations with 
sparse observations where points that are closer together in space and time—
and which have similar covariate patterns—are expected to have similar LRI 
prevalence. Because the prevalence of LRIs has been shown to be influenced by 
social, structural and environmental factors2,32, we selected a set of 12 continuous 
geographical covariates based both on previous mapping efforts and past GBD 
analyses of LRI for inclusion in the model (Supplementary Table 3)33. Potential 
non-linear relationships between these covariates and LRI prevalence were 
incorporated through the use of a stacked generalization technique33, which is 
further detailed in Section 3.2 of the Supplementary Information. Sensitivity 
analyses were carried out to assess sensitivity to hyper-prior specification and 
are described in detail in Section 5.4 of the Supplementary Information. For the 
prevalence estimates in 2017, due to data limitations, we assumed the spatial 
pattern matched that of 2016. Estimated prevalence rates were converted into 
incidence rates using an average duration of an episode of LRI of 7.8 d. Using 
country- and year-specific CFRs from the GBD 2017 study, we converted 
our incidence rates into mortality rates. Posterior distributions of all model 
parameters and hyperparameters were estimated using the statistical package 
R-INLA v.18.07.12 (ref. 34,35). Uncertainty was calculated by taking 1,000 draws 
from the posterior joint distribution of the model; each point value is reported 
with an uncertainty interval that represents the 2.5th and 97.5th percentiles 
of those 1,000 draws. Additional methodological details can be found in the 
Supplementary Information.
We used two post-hoc approaches to identify regions or clusters of higher-
than-average burden from our estimates: the Getis–Ord local G statistic36 and a 
simple arithmetic method. The Getis–Ord local G statistic, which in this study 
relates each first-level administrative subdivision and its neighbours to the total set 
of first-level administrative subdivisions, identifies whether a division is collectively 
significantly higher (hotspot) or lower (coldspot) than the expected value as 
informed by the total set36. We then conducted a sensitivity analysis to determine 
the impact of the spatial and temporal correlations structures inherent to the 
Bayesian geostatistical approach on the clustering hotspot analysis. Moreover, 
we conducted the same analysis on each draw from the posterior distribution of 
mortality risk and summarized the frequency for which each first administrative 
division was identified as a ‘hotspot’. This sensitivity analysis avoids the use of the 
standard reference distribution for the local statistic and as such is adjusting for the 
spatial variation in the background population size. The second method identified 
clusters of higher-than-average burden arithmetically by identifying all divisions 
with the highest estimated mortality rate that account for a fixed percentage of 
all deaths and then counting the number of contiguous divisions identified. It is 
important to note that for both analyses, ‘hotspot’ is a relative term, comparing the 
risk in one area to other areas within a single year. Overall burden has decreased 
from 2000 to 2017, so locations that are identified as hotspots in 2017 would not 
have qualified in 2000. To emphasize this, when identifying clusters of remaining 
high risk in 2017, we refer to them as residual hotspots.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
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For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
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A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
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A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
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AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
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Data collection No primary data collection was carried out for this analysis.
Data analysis This analysis was carried out using R version 3.5.0. The main geostatistical models were fit using R-INLA version 18.07.12. All code used 
for these analyses is publicly available online at http://ghdx.healthdata.org/.
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- Accession codes, unique identifiers, or web links for publicly available datasets 
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- A description of any restrictions on data availability
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that are not publicly available due to restrictions by the data provider and which were used under license for the current study. A detailed table of data sources and 
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Sample size Sample size was calculated as the number of unique data source-location pairs with observations of LRI prevalence. This sample size is 
reported in the methods section: "We compiled 191 household surveys...from 2000 to 2017 with geocoded information from 56,628 total 
data points, 53,529 corresponding to survey clusters and 3,036 to subnational polygon boundaries."
Data exclusions For a survey to be considered for this analysis, we required information on whether a child had been coughing recently and had difficulty 
breathing. Ideal datasets captured additional information about symptoms in the chest and fever status. Select data sources were excluded 
from the analysis due to: missing survey weights for areal data, incomplete sampling (e.g., only a specific age range), or untrustworthy data 
(as determined by the survey administrator or by inspection). 
Replication This is an observational study using many years of survey and surveillance data and could be replicated.
Randomization This analysis is an observational mapping study and there were no experimental groups.
Blinding Blinding was not relevant to this study, as it was an observational study using survey and surveillance data.
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